Table 2.

Reactivity of expanded panel of CD20 mAbs

GroupAxP reactivityAntibody designationHomotypic aggregationCD20 translocation
 I None CAT 13.6E126 − ++++ 
II Weak 2H76, 1C0-1652 − ++++, ++  
  AT802 ++++ ++++ 
III Intermediate 1F56, B-H202, MEM-972 − +++  
IV High B16, Bly12 ++++ − 
  Rituxan3 ++ ++++ 
  NK12, PDR782, F4B13661, LT205, L275, CAT 13.7H82 − +++ to ++++ 
GroupAxP reactivityAntibody designationHomotypic aggregationCD20 translocation
 I None CAT 13.6E126 − ++++ 
II Weak 2H76, 1C0-1652 − ++++, ++  
  AT802 ++++ ++++ 
III Intermediate 1F56, B-H202, MEM-972 − +++  
IV High B16, Bly12 ++++ − 
  Rituxan3 ++ ++++ 
  NK12, PDR782, F4B13661, LT205, L275, CAT 13.7H82 − +++ to ++++ 

Superscripts indicate the number of times each antibody was tested for reactivity against the m/h AxP chimera (construct C). At least 2 homotypic aggregation and translocation experiments were performed for each antibody, and were scored as described in “Materials and methods.”

Close Modal

or Create an Account

Close Modal
Close Modal